A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model.

Trial Profile

A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Ocular Therapeutix
  • Most Recent Events

    • 05 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2016 According to an Ocular Therapeutix media release, the company expects to submit an NDA supplement tot he US FDA for ocular itching associated with allergic conjunctivitis in the fourth quarter of 2016.
    • 22 Oct 2015 Primary endpoint "Ocular itching" has been met, according to an Ocular Therapeutix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top